Alp Basaran

Counsel, New York



Alp Basaran is a counsel in the Mergers & Acquisitions Group, resident in the New York office.

Alp advises public and private companies, as well as private equity firms, in a variety of US and international mergers, acquisitions, dispositions, investments, joint ventures, tender offers, spin-offs, restructurings and financings. Alp also counsels companies on shareholder activism, securities law compliance and corporate governance matters. Sectors in which Alp has had substantial transactional involvement include health care, materials, industrials, technology and energy.

Previously, Alp was the founder and CEO of Aslan Capital Advisors LLC, an independent advisory firm, and he ran for US Congress.

Bars and Courts
New York State Bar
UCLA School of Law
Vanderbilt University


Representative matters prior to joining White & Case include:

Representation of New 2nd Capital in its acquisition of lumber and boat manufacturing companies.

Representation of PeakEquity Partners in its investment in CareerArc Group, a software company.

Representation of Southside Group of Companies in its sale of a majority equity interest to Frazier Healthcare Partners.

Representation of Elwyn Pharmacy Group LLC in its sale of a majority equity interest to a portfolio company of ACON Investments, LLC.

Representation of UroGPO in its sale of a majority interest to Nautic Partners.

Representation of Genoa Healthcare in its acquisition of Medication Management Systems, Inc.

Representation of Marsh McLennan Agency in connection with asset and stock acquisitions of regional insurance agencies.

Representation of Deloitte LLP in its design, implementation and restructuring of global legal entity structures.

Representation of Danaher Corporation in multiple transactions, including its:

  • split into two Fortune 500 companies with a combined market capitalization in excess of US$60 billion.
  • US$13.8 billion acquisition of Pall Corporation.
  • US$2.6 billion Reverse Morris Trust transaction involving the split-off of its communications business and merger with NetScout Systems, Inc.
  • US$225 million acquisition of a 75 percent interest in Implant Direct and combination with Sybron Dental Specialties, Inc.

Representation of Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc.) in multiple transactions, including its:

  • US$1 billion acquisition of Sprout Pharmaceuticals.
  • US$8.7 billion acquisition of Bausch + Lomb from Warburg Pincus LLC.
  • US$166 million acquisition of Synergetics USA, Inc.
  • purchase of an option to acquire Ideal Implant from Dr. Robert S. Hamas and shareholders.

Representation of Copersucar S.A. in corporate matters relating to its majority interest in Eco-Energy Global Biofuels, LLC.

Representation of Kelso & Company, L.P. in the formation of a joint venture with funds managed by StoneRiver Group, L.P. and the merger of Progressive Medical, Inc. with PMSI, Inc.

Representation of Butamax Advanced Biofuels LLC, a joint venture between E. I. du Pont de Nemours and Company and BP plc, in its lease of capital equipment to and intellectual property licensing arrangements with Highwater Ethanol LLC for the retrofit of an ethanol plant to produce biobutanol.

Representation of E. I. du Pont de Nemours and Company in multiple transactions, including its:

  • US$4.9 billion sale of DuPont Performance Coatings to The Carlyle Group.
  • proposed sale of its powder coatings business.
  • proposed sale of its cyanide business.
  • US$6.6 billion acquisition of Danisco A/S by tender offer.

Representation of the Warnaco Group, Inc. in its US$2.9 billion acquisition by PVH Corp. to unite "The House of Calvin Klein."

Representation of Endurance Specialty Holdings Ltd. in its proposed US$3.2 billion acquisition of Aspen Insurance Holdings Limited.

Representation of Formation Capital, LLC in its acquisition of all of the assets of Trident USA Health Services, LLC and National Hospice Holdings, LLC, and the formation of a joint venture with the sellers.

Representation of Sentinel Capital Partners in its acquisition of PlayCore.

Representation of Endo Health Solutions Inc. in its proposed US$105 million acquisition of NuPathe Inc.

Representation of Pfizer Inc. in the carve-out restructuring of its animal health business into a separate company called Zoetis Inc. and in the US$2.6 billion initial public offering of Zoetis.

Representation of Horsehead Holding Corp. in its acquisition of Zochem Inc. from HudBay Mining & Smelting.

Representation of Fortress Investment Group LLC in its 80 percent acquisition of American General Finance Inc., a company with US$20 billion in assets, from American International Group, Inc.